{"name":"Recursion Pharmaceuticals, Inc.","slug":"recursion","ticker":"RXRX","exchange":"NASDAQ","domain":"recursion.com","description":"Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. T","hq":"Salt Lake City, UT","founded":2017,"employees":"600","ceo":"Chris Gibson","sector":"AI Drug Discovery","stockPrice":3.1,"stockChange":0.05,"stockChangePercent":1.64,"marketCap":"$1.6B","metrics":{"revenue":66408000,"revenueGrowth":-56.1,"grossMargin":0,"rdSpend":0,"netIncome":-559776000,"cash":654473024,"dividendYield":0,"peRatio":-3.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"olusa patent cliff ($0.0B at risk)","drug":"olusa","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Recursion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Recursion Pharmaceuticals reported its fourth-quarter and full-year 2023 financial results, highlighting a net loss of $44.4 million and a cash balance of $434.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Recursion Pharmaceuticals Announces Collaboration with the National Institutes of Health (NIH)","summary":"Recursion Pharmaceuticals entered into a collaboration with the NIH to develop novel therapeutics for rare genetic disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOcXhQWmVTZ0dBVWFzdGE2dk9hdzktTUYtVXdPR0FuTkxSTW0zV2UxQmlRcjN3MW1MMjVaalltUnU4NmM3RVVQNVN1SE9YNkVXbExKd0N1V0w0cS1PZndyYzdjQUNNRWI4dlU1b2dSWUktQ0xZZF9HOVI1TTRScmhoWFhNLVVJV2lTY3dEaFRNSTBFRU5yckZjcUt2eWo1T2s1M3h6RmdlQm9XeUhVdjFSbA?oc=5","date":"2026-02-23","type":"pipeline","source":"Finviz","summary":"Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts - Finviz","headline":"Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOZjlSSzlRUlVnZWpKZjktYTYxeHlUWGh5ZnllcUpTbE9qTVEyYTlNMlBPbFM0SU02bzRiUHlYUWZ5S01wMk1kWE9kaW9KVU5iSlk1aGJoLTBBWjF2RFNQTk9yV1dna0RMVEQzZDZrRzBsWUJQTkFWQlEzVURxTzlwZ0xWNFRUeEZHaTE3SG5Ldw?oc=5","date":"2026-02-23","type":"deal","source":"Yahoo Finance","summary":"The Bull Case For Recursion Pharmaceuticals (RXRX) Could Change Following Nvidia’s Exit And ARK’s Big Buy-In - Yahoo Finance","headline":"The Bull Case For Recursion Pharmaceuticals (RXRX) Could Change Following Nvidia’s Exit And ARK’s Big Buy-In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPRU8tSGNRQUlKNGZfVE9sY0kya0ppM1pYTl9HWmdtUHl0dGE3X1VrcFpFUE1ndmRlM1RySDBJZGx3M1N1WkE2ZVphTTJMTnhld25jdlJXNUdyY2g5MjVMbjMtSVNFdVVwX0hjaGNqX29DZ2pDb0ZDY1dJblhVUl90bVlJeXdBNm9KUXlNT054aWRNeXhG?oc=5","date":"2026-02-17","type":"earnings","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - Yahoo Finance","headline":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFB5REJVRi03U05PU3BoYmplNG00Q3d5QUJFUE5VdlBleXMwTUdHNVQ3ZXhwVW5YT05lN1EzNEtlQl9sTDRoUmNDVWY1MDh5V2MyZkNnd0ppeTFEX0ttNVd1TmJHM1IteTYzSVJqclVMVWVxOTBobFNjTDgtZHI1Zw?oc=5","date":"2026-01-25","type":"pipeline","source":"Yahoo Finance","summary":"Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative - Yahoo Finance","headline":"Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNVnpZZGxsSHBKU2d5Qy1vSlQ2aGlRZ1JkQWFFSW5TNTVVdzRRTzJaZ1l1U2p3d3BoZ3UwTmc1NVRCM2tvRXV5c1NrTi1ubmZkNWFZX2Z1RE16R21uUkxYMlFqV1NIaGw3VmszM1p4aHBSOEU0WXVfLThqM0tndHMtVnpYMTlGWXZObGNOU3VB?oc=5","date":"2026-01-20","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Yahoo Finance","headline":"Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOOHlEczJmb3hxdU9zb2FwZUppeHpzb3dYYk1ZTzZROEtYQ0VodGdFZV9jNWI1WTZpUnlwbEJ4Q1F5Wk5FMElDNDUxeXR6QUltTHAwcVp0MExaVjRySklWT0VNdFIwRmpadnZTVXpQR0k1dUFFaWdINmZiNHlMaXFBWFpsaDhpMlI1ajBzSlY3QVNRSFNSQ25kdA?oc=5","date":"2026-01-18","type":"pipeline","source":"Yahoo Finance","summary":"JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects - Yahoo Finance","headline":"JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOajY3dk84YXZYLWdUa1NQZ1NRemZWYTFkR0RXX1cyalFScjA3ajVWLTJLUEVKMjNXcGY3NEM2enN6U04tMk5SOWxwVlhVdFF3Q2Zzc2NQcEpreWNOQ3k1RHRvQkpmTDBuUkNyYTh2YjRKOFpCVXBSaTIwaDBkYlpDbFdwTDluOEpfSmFTbmlhQmFTZG1saHVydkxn?oc=5","date":"2026-01-02","type":"pipeline","source":"Yahoo Finance","summary":"JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Yahoo Finance","headline":"JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPWUFQVUppcWEtaDRVVDNCOUJZRTN2aVM2VjJZY1VxRFFJZkR3WUtUTTBSNW9BN3ZNamFpNmNqSk5WRkUzc3A5MXRENk1QSUp0Y0dycmQ1WWxwQms4UmNJanhFS0o4enh2czhBLXFkSUE1VXAwczVUREVVTE5pQTN6b0tYTXhkYXBUcTg1ck5Ua2ZqUnlkM2FIcQ?oc=5","date":"2026-01-01","type":"deal","source":"The Motley Fool","summary":"Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - The Motley Fool","headline":"Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQS0lwYVNWWVlFLUZORzYyT2VBU3FrSDdPa19RUWhTeUxOczQ4WFByR2hVc2lta0o1aTQ2d2pzRXJBTUkxSkpIdDFuTEIybTUxdXRXMHFQVUt1S3Z4WThiekJZRGRaRHNkRVRYcHM3TDN0bkVKZzFHTjR6XzNURlF1ZjcxVkk0YUVZaFZmNzd3?oc=5","date":"2025-12-21","type":"deal","source":"Yahoo Finance","summary":"Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Yahoo Finance","headline":"Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNLVlKUnVDcmtCYkw1UTMzNHo5VV9FUE9CSFU1RmZaNXVScGFYN2JXbG1heDdob2pLYTVDNGRXQmZIT3k1cHNyZ3I2RHIxQl90YmlhUUR1bC1PYThySmZWdXd4cm1EMUpaSHVpa0VwVm83T2RDZ1BuWUdtNnhKVVdLQUZvS0RDa1NxbnZiVkxQQVJRNU9za3JZTnBMVks2U0pHSHJOaXNYZDlDOTNQYUNCWWh0eTZZdw?oc=5","date":"2025-12-18","type":"deal","source":"Seeking Alpha","summary":"Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX) - Seeking Alpha","headline":"Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOTlFqdkl0VHdrS2JkZE1jaGt0Qk5XWGtnMDBIa3VRTEs0MmZjemYwT0JkRUt5Vm9ZMVhXekdaWlFDaEVFd2ZZSzZZMUFKckxURFZoUExSSWt1em1PQWxqbjlRUWxIaDVfRFJWOHVpZ29yR1BrMmk1TEJ3Sy1PRXV5X2puNjZTUWNEcmotSHdB?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Yahoo Finance","headline":"Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNSDJKMlpBLVBSdGVza1otWm1PZU52R09BTWgtR3QwWWFZV0I1emQxdWYxMXN2SnhaMEp3UC04eTZ6c1N0TXBXajJSbGprMHB0YTE2cGlxMDhVWnZGQjUyS1JVSV9vdVZjRjJqV1pWSXl6U0VVREE5VjNMZFJIVDJPLTk2U1JMTnFnT2s1dzdzai0xUQ?oc=5","date":"2025-09-21","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Yahoo Finance","headline":"Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances","sentiment":"neutral"}],"patents":[{"drugName":"olusa","drugSlug":"olusa","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Vertex Pharmaceuticals","Biogen","Pfizer"],"therapeuticFocus":["Rare Genetic Disorders","Cancer"],"financials":{"source":"yahoo_finance","revenue":74256000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":74256000},{"period":"2024-12-31","value":58488000},{"period":"2023-12-31","value":43876000},{"period":"2022-12-31","value":39681000}],"grossProfit":3303000,"grossProfitHistory":[{"period":"2025-12-31","value":3303000},{"period":"2024-12-31","value":13250000},{"period":"2023-12-31","value":1289000},{"period":"2022-12-31","value":-8594000}],"rdSpend":475271000,"rdSpendHistory":[{"period":"2025-12-31","value":475271000},{"period":"2024-12-31","value":314421000},{"period":"2023-12-31","value":241226000},{"period":"2022-12-31","value":155696000}],"sgaSpend":176589000,"operatingIncome":-648132000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-648132000},{"period":"2024-12-31","value":-479004000},{"period":"2023-12-31","value":-350060000},{"period":"2022-12-31","value":-245727000}],"netIncome":-644759000,"netIncomeHistory":[{"period":"2025-12-31","value":-644759000},{"period":"2024-12-31","value":-463661000},{"period":"2023-12-31","value":-328066000},{"period":"2022-12-31","value":-239476000}],"eps":-1.44,"epsHistory":[{"period":"2025-12-31","value":-1.44},{"period":"2024-12-31","value":-1.69},{"period":"2023-12-31","value":-1.58},{"period":"2022-12-31","value":-1.36}],"cash":743294000,"cashHistory":[{"period":"2025-12-31","value":743294000},{"period":"2024-12-31","value":594350000},{"period":"2023-12-31","value":391565000},{"period":"2022-12-31","value":549912000}],"totalAssets":1474130000,"totalLiabilities":343265000,"totalDebt":77965000,"equity":1130865000,"operatingCashflow":-371808000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-371808000},{"period":"2024-12-31","value":-359174000},{"period":"2023-12-31","value":-287780000},{"period":"2022-12-31","value":-83524000}],"capex":-8627000,"capexHistory":[{"period":"2025-12-31","value":-8627000},{"period":"2024-12-31","value":-17045000},{"period":"2023-12-31","value":-12552000},{"period":"2022-12-31","value":-37359000}],"freeCashflow":-380435000,"dividendsPaid":null,"buybacks":null,"employees":600,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":34591000,"ebit":-121758000,"ebitda":-102085000,"period":"2026-03-31","revenue":6301000,"epsBasic":-0.22,"netIncome":-117504000,"rdExpense":87896000,"epsDiluted":-0.22,"grossProfit":-6189000,"operatingIncome":-128505000},{"sga":33657000,"ebit":-108112000,"ebitda":-88634000,"period":"2025-12-31","revenue":35351000,"epsBasic":-0.21,"netIncome":-108122000,"rdExpense":95940000,"epsDiluted":-0.21,"grossProfit":21076000,"operatingIncome":-108334000},{"sga":41628000,"ebit":-161417000,"ebitda":-140374000,"period":"2025-09-30","revenue":4983000,"epsBasic":-0.36,"netIncome":-162253000,"rdExpense":121062000,"epsDiluted":-0.36,"grossProfit":-9704000,"operatingIncome":-172202000},{"sga":46653000,"ebit":-171417000,"ebitda":-147568000,"period":"2025-06-30","revenue":19103000,"epsBasic":-0.41,"netIncome":-171897000,"rdExpense":128636000,"epsDiluted":-0.41,"grossProfit":-1058000,"operatingIncome":-176227000},{"sga":54650000,"ebit":-202137000,"ebitda":-182806000,"period":"2025-03-31","revenue":14818000,"epsBasic":-0.5,"netIncome":-202487000,"rdExpense":129634000,"epsDiluted":-0.5,"grossProfit":-7011000,"operatingIncome":-191368000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.1,"previousClose":3.05,"fiftyTwoWeekHigh":7.18,"fiftyTwoWeekLow":2.8,"fiftyTwoWeekRange":"2.8 - 7.18","fiftyDayAverage":3.36,"twoHundredDayAverage":4.41,"beta":1.05,"enterpriseValue":1034112832,"forwardPE":-3.5,"priceToBook":1.6,"priceToSales":24.74,"enterpriseToRevenue":15.57,"enterpriseToEbitda":-2.06,"pegRatio":0,"ebitda":-501225984,"ebitdaMargin":0,"freeCashflow":-177795632,"operatingCashflow":-320952000,"totalDebt":72375000,"debtToEquity":7.1,"currentRatio":5.47,"returnOnAssets":-27.7,"returnOnEquity":-57.2,"analystRating":"2.5 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":6.57,"targetHighPrice":10,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.3,"institutionHeldPercent":68.1,"sharesOutstanding":524677865,"floatShares":512964130,"sharesShort":171321811,"shortRatio":15.03,"shortPercentOfFloat":32.3,"epsTrailing":-1.16,"epsForward":-0.88,"revenuePerShare":0.14,"bookValue":1.93,"officers":[{"age":42,"name":"Dr. Christopher C. Gibson Ph.D.","title":"Co-Founder, Chairman & Interim Executive Advisor"},{"age":41,"name":"Dr. Najat  Khan Ph.D.","title":"CEO, President & Director"},{"age":48,"name":"Mr. Ben R. Taylor","title":"CFO & President of Recursion UK"},{"age":null,"name":"Mr. Sid  Jain","title":"Senior Vice President of Clinical Development & Data Science"},{"age":54,"name":"Dr. Vicki L. Goodman M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Elizabeth  Bruckheimer Ph.D.","title":"Vice President of Clinical Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.recursion.com","phone":"385 269 0203"}}